Claims
- 1. A method of combating a mood disorder in a subject experiencing or susceptible to same, comprising administering to said subject an effective amount of a therapeutic composition comprising at least one compound selected from the group consisting of:
- 2. The method of claim 1, wherein said mood disorder comprises depression.
- 3. The method of claim 1, wherein said mood disorder comprises a pathological mental and/or emotional state.
- 4. The method of claim 1, wherein said mood disorder comprises bipolar manic-depression or seasonal affective disorder.
- 5. The method of claim 1, wherein said therapeutic composition is administered by an administration modality selected from the group consisting of oral, rectal, topical, sub-lingual, mucosal, nasal, ophthalmic, subcutaneous, intramuscular, intravenous, transdermal, spinal, intrathecal, intra-articular, intra-arterial, sub-arachnoid, bronchial, lymphatic, and intra-uterine administration.
- 6. The method of claim 1, wherein said therapeutic composition further comprises another mood disorder-combating agent.
- 7. The method of claim 6, wherein said another mood disorder-combating agent comprises an agent selected from the group consisting of tricyclic antidepressants, MAO inhibitors, 5-HT agonists and antagonists, aminoketones, serotonin reuptake inhibitors and adrenergic reuptake inhibitors.
- 8. A composition for combating a mood disorder in a subject experiencing or susceptible to same, comprising at least one compound selected from the group consisting of:
- 9. The composition of claim 8, in a unitary dose form.
- 10. The composition of claim 9, wherein said unitary dose form comprises an oral dose form.
- 11. The composition of claim 8, further comprising another mood disorder-combating agent.
- 12. The composition of claim 11, wherein said another mood disorder-combating agent comprises an agent selected from the group consisting of tricyclic antidepressants, MAO inhibitors, 5-HT agonists and antagonists, aminoketones, serotonin reuptake inhibitors and adrenergic reuptake inhibitors.
- 13. A dose form comprising a patch affixable to a corporeal locus, and containing a composition for combating a mood disorder in a subject experiencing or susceptible to same, comprising at least one compound selected from the group consisting of:
- 14. The dose form of claim 13, wherein said patch comprises a transdermal patch.
- 15. The dose form of claim 13, wherein said patch comprises a transmucosal patch.
- 16. The dose form of claim 13, wherein said composition comprises another mood disorder-combating agent.
- 17. The dose form of claim 16, wherein said another mood disorder-combating agent comprises an agent selected from the group consisting of tricyclic antidepressants, MAO inhibitors, 5-HT agonists and antagonists, aminoketones, serotonin reuptake inhibitors and adrenergic reuptake inhibitors.
- 18. A method of combating a mood disorder in a subject experiencing or susceptible to same, comprising administering to said subject an effective amount of a therapeutic composition comprising a diarylmethylpiperazine compound of the general formula:
- 19. A therapeutic composition for combating a mood disorder in a subject experiencing or susceptible to same, comprising one or more diarylmethylpiperazine compounds of the general formula:
- 20. The composition of claim 19 further comprising another mood disorder-combating agent selected from the group consisting of tricyclic antidepressants, MAO inhibitors, and 5-HT agonists and antagonists, aminoketones, serotonin reuptake inhibitors and adrenergic reuptake inhibitors.
- 21. A composition for combating a mood disorder in a subject experiencing or susceptible to same, comprising a diarylmethylpiperazine compound of the general formula:
- 22. The composition according to claim 21, wherein the diarylmethylpiperazine compound is administered in an oral dosage form.
- 23. The composition according to claim 21, further comprising another mood disorder-combating agent.
- 24. The composition according to claim 21, further comprising another mood disorder-combating agent that is not a delta opioid receptor agonist.
- 25. The composition of claim 23, wherein said another mood disorder-combating agent comprises an agent selected from the group consisting of tricyclic antidepressants, MAO inhibitors, 5-HT agonists and antagonists, aminoketones, serotonin reuptake inhibitors and adrenergic reuptake inhibitors.
- 26. A method of combating a mood disorder in a subject experiencing or susceptible to same, comprising administering to said subject an effective amount of a therapeutic composition comprising a diarylmethylpiperazine compound of the general formula:
- 27. The method of claim 26, wherein the composition further comprises another mood disorder-combating agent.
- 28. The method of claim 27, wherein the another mood disorder-combating agent is selected from the group consisting of tricyclic antidepressants, MAO inhibitors, and 5-HT agonists and antagonists, aminoketones, serotonin reuptake inhibitors and adrenergic reuptake inhibitors.
- 29. A therapeutic composition for combating a mood disorder in a subject experiencing or susceptible to same, comprising a diarylmethylpiperazine compound of the formula:
- 30. The therapeutic composition of claim 29, wherein the composition is in an effective amount to combat a mood disorder in a subject experiencing or susceptible to same.
- 31. The therapeutic composition of claim 30, wherein the composition further comprises another mood disorder-combating agent.
- 32. A therapeutic composition for combating a mood disorder in a subject experiencing or susceptible to same, comprising a diarylmethylpiperazine compound of the formula:
- 33. The therapeutic composition of claim 32, wherein the compound is in an effective amount to combat a mood disorder in a subject experiencing or susceptible to same.
- 34. The therapeutic composition of claim 33, wherein the composition further comprises another mood disorder-combating agent.
- 35. The therapeutic composition of claim 33, wherein the composition is orally administerable.
- 36. A therapeutic composition for combating a mood disorder in a subject experiencing or susceptible to same, comprising a diarylmethylpiperazine compound of the formula:
- 37. The therapeutic composition of claim 36, wherein the compound is in an effective amount to combat a mood disorder in a subject experiencing or susceptible to same.
- 38. The therapeutic composition of claim 37, wherein the composition further comprises another mood disorder-combating agent.
- 39. The therapeutic composition of claim 36, wherein the composition is orally administerable.
- 40. A therapeutic composition for combating a mood disorder in a subject experiencing or susceptible to same, comprising a diarylmethylpiperazine compound of the formula:
- 41. The therapeutic composition of claim 40, wherein the compound is in an effective amount to combat a mood disorder in a subject experiencing or susceptible to same.
- 42. The therapeutic composition of claim 41, wherein the composition further comprises another mood disorder-combating agent.
- 43. The therapeutic composition of claim 40, wherein the composition is orally administerable.
- 44. A therapeutic composition for combating a mood disorder in a subject experiencing or susceptible to same, comprising a diarylmethylpiperazine compound of the formula:
- 45. The therapeutic composition of claim 44, wherein the compound is in an effective amount to combat a mood disorder in a subject experiencing or susceptible to same.
- 46. The therapeutic composition of claim 45, wherein the composition further comprises another mood disorder-combating agent.
- 47. The therapeutic composition of claim 44, wherein the composition is orally administerable.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority from U.S. Provisional Patent Application No. 60/340,084 filed on Oct. 29, 2001 and U.S. Provisional Patent Application No. 60/337,887 filed on Nov. 2, 2001.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60340084 |
Oct 2001 |
US |
|
60337887 |
Nov 2001 |
US |